AB Science SA (Euronext – FR0010557264 – AB) announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...

After years of disappointment, things might seem to be looking up for the amyotrophic lateral sclerosis patient community. Two weeks ago they got a new drug approved by the FDA, and now French biotech ...

Ab Science ( (ABSCF)) has released its Q2 earnings. Here is a breakdown of the information Ab Science presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...

Update on the AB8939 microtubule program and in particular on the ability of AB8939 to generate a response on MECOM rearrangement AB Science provided an update on the microtubule program AB8939.

(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), confirms the filing to EMA for the ...

PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION ...

AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Paris, October 10, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...

The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. The issue of the ABSAs, ...

France's AB Science suffered another setback in its years-long effort to gain traction for its lead compound, masitinib, which it has been developing for both veterinary and human medicine. The ...